From the Guidelines
Prolia (Denosumab) is administered via subcutaneous injection.
Administration Details
- The recommended dose of denosumab is 120 mg administered subcutaneously every 4 weeks 1.
- This dosing frequency is consistent across different types of cancer, including breast cancer, prostate cancer, and multiple myeloma 1.
- It is essential to note that denosumab should not be administered intravenously, as this is not an approved route of administration for this medication.
- Patients with impaired renal function or those on hemodialysis may require closer monitoring for hypocalcemia and hypophosphatemia, but the dose and schedule of denosumab do not need to be adjusted based on renal function alone 1.
Important Considerations
- Before initiating denosumab therapy, patients should have a dental examination and complete any necessary invasive dental procedures to minimize the risk of osteonecrosis of the jaw 1.
- Patients should also be advised to take supplemental calcium and vitamin D to prevent hypocalcemia 1.
From the FDA Drug Label
Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen. The administration route of Prolia (Denosumab) is subcutaneous.
- The recommended injection sites are the upper arm, upper thigh, or abdomen.
- The dose is administered every 6 months 2.
From the Research
Administration Route of Prolia (Denosumab)
- The administration route of Prolia (Denosumab) is via subcutaneous injection 3, 4.
- Denosumab is administered once every 6 months 3, 4, 5, 6.
- The subcutaneous injection of denosumab may be a preferred method of administration and may improve adherence to treatment compared with other osteoporosis treatments 3.
- The dose of denosumab is 60 mg, administered subcutaneously every 6 months 4, 6.